Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mirum Pharmaceuticals (MIRM) Exchange Rate Effect (2020 - 2025)

Historic Exchange Rate Effect for Mirum Pharmaceuticals (MIRM) over the last 6 years, with Q3 2025 value amounting to $349000.0.

  • Mirum Pharmaceuticals' Exchange Rate Effect rose 29659.09% to $349000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.3 million, marking a year-over-year increase of 108473.68%. This contributed to the annual value of -$1.3 million for FY2024, which is 87518.8% down from last year.
  • Latest data reveals that Mirum Pharmaceuticals reported Exchange Rate Effect of $349000.0 as of Q3 2025, which was up 29659.09% from $2.2 million recorded in Q2 2025.
  • Over the past 5 years, Mirum Pharmaceuticals' Exchange Rate Effect peaked at $2.2 million during Q2 2025, and registered a low of -$1.4 million during Q4 2024.
  • For the 5-year period, Mirum Pharmaceuticals' Exchange Rate Effect averaged around $122833.3, with its median value being $4000.0 (2021).
  • In the last 5 years, Mirum Pharmaceuticals' Exchange Rate Effect tumbled by 173333.33% in 2022 and then skyrocketed by 636666.67% in 2023.
  • Over the past 5 years, Mirum Pharmaceuticals' Exchange Rate Effect (Quarter) stood at $5000.0 in 2021, then skyrocketed by 1600.0% to $85000.0 in 2022, then increased by 27.06% to $108000.0 in 2023, then plummeted by 1376.85% to -$1.4 million in 2024, then skyrocketed by 125.31% to $349000.0 in 2025.
  • Its last three reported values are $349000.0 in Q3 2025, $2.2 million for Q2 2025, and $1.1 million during Q1 2025.